Home / Business and Economy / Roche Licenses Parkinson's Drug for $1.27B
Roche Licenses Parkinson's Drug for $1.27B
5 Oct
Summary
- Roche will pay up to $1.27 billion for Alector's Parkinson's drug license.
- Genentech will pay $100 million upfront and milestones.
- Alector's shares surged 72% on the deal announcement.
Swiss drugmaker Roche has agreed to a licensing deal potentially worth up to $1.27 billion for an experimental Parkinson's disease treatment developed by Alector. The agreement, announced on Monday, October 5th, involves Genentech, a subsidiary of Roche.
Genentech will make an upfront payment of $100 million to Alector. Further payments, totaling up to $1.17 billion, are tied to the treatment achieving specific development, regulatory, and sales milestones. Alector is also eligible to receive royalties on future sales.
This major collaboration significantly boosted Alector's market standing, with its shares experiencing a substantial surge of 72% in premarket trading immediately following the news of the deal.
